-
Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
21 Sep 2021 22:33 GMT
… , acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating … , please visit . ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. Every Second …
-
The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US
09 Jun 2021 14:00 GMT
… (Biotech Stocks Hitting 52-week Highs June 8)
Agios Pharmaceuticals, … Meeting With FDA Over Lead Drug For The Treatment of Chronic … appropriate use of pneumococcal vaccines in adults.
Transmedics … this patent under the Arcalyst License Agreement.
The stock …
-
Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
04 May 2021 11:59 GMT
… best-in-class treatment option and support … developing and commercializing therapeutic medicines for patients suffering … clinical trials, including for the Phase 2 clinical trial; … release. ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. …
-
Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients
12 Apr 2021 11:30 GMT
… trial ongoing – HAMILTON, Bermuda, April 12, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals … duration of vaccine protection highlight … FDA granted Orphan Drug designation to mavrilimumab for the treatment … medical need. Kiniksa’s portfolio of assets, ARCALYST …
-
Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
01 Apr 2021 12:00 GMT
… Regeneron Pharmaceuticals, Inc. (Regeneron). Upon the approval by the FDA … vaccine, before you begin treatment with ARCALYST.
ARCALYST can cause serious side effects:
Medicines … ARCALYST; drug substance and/or drug … Corporation, AbbVie Biotechnology Ltd., …
-
Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
18 Mar 2021 20:30 GMT
… Regeneron Pharmaceuticals, Inc. (Regeneron) and received initial FDA approval in February 2008 for the treatment … vaccine, before you begin treatment with ARCALYST.
ARCALYST can cause serious side effects:
Medicines … ARCALYST; drug substance and/or drug …
-
Arcalyst Gets FDA Nod as First Therapy for Recurrent Pericarditis
26 Mar 2021 00:31 GMT
… Food and Drug Administration (FDA) has approved rilonacept (Arcalyst) to … to nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids … on 98% of trial days, whereas those … drug.
The FDA label also advises that patients should avoid live vaccines …
-
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
28 Feb 2021 20:53 GMT
… cancer, Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) cholesterol drug Evkeeza and … to a class of medicines called HIF-PH inhibitors … the FDA under the brand name Arcalyst for the treatment of … In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions …
-
Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
23 Nov 2020 13:00 GMT
… rilonacept treatment in the trial improved … Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the FDA for the treatment … live vaccine while taking ARCALYST. It … medical treatment if warranted. Treatment with immunosuppressants, including ARCALYST …
-
Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020
17 Nov 2020 13:00 GMT
… and Drug Administration (FDA)-approved label for the treatment of Cryopyrin … with medical treatment if warranted. Treatment with immunosuppressants, including ARCALYST, may … release. ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. …
About
© 1995-2021